• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Epidemiological analysis of the first 1000 cases of SARS-CoV-2 lineage BA.1 (B.1.1.529, Omicron) compared with co-

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2022 Jul 12.
doi: 10.1111/irv.13021. Online ahead of print.
Epidemiological analysis of the first 1000 cases of SARS-CoV-2 lineage BA.1 (B.1.1.529, Omicron) compared with co-circulating Delta in Wales, UK


Nicole Pacchiarini[SUP] 1 [/SUP], Clare Sawyer[SUP] 1 [/SUP], Christopher Williams[SUP] 1 [/SUP], Daryn Sutton[SUP] 1 [/SUP], Christopher Roberts[SUP] 1 [/SUP], Felicity Simkin[SUP] 1 [/SUP], Grace King[SUP] 1 [/SUP], Victoria McClure[SUP] 1 [/SUP], Simon Cottrell[SUP] 1 [/SUP], Helen Clayton[SUP] 2 [/SUP], Andrew Beazer[SUP] 3 [/SUP], Catie Williams[SUP] 3 [/SUP], Sara M Rey[SUP] 3 [/SUP], Thomas R Connor[SUP] 3 4 [/SUP], Catherine Moore[SUP] 5 [/SUP]



Affiliations

Abstract

Background: The Omicron (lineage B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wales, UK, on 3 December 2021. The aim of the study was to describe the first 1000 cases of the Omicron variant by demographic, vaccination status, travel and severe outcome status and compare this to contemporaneous cases of the Delta variant.
Methods: Testing, typing and contact tracing data were collected by Public Health Wales and analysis undertaken by the Communicable Disease Surveillance Centre (CDSC). Risk ratios for demographic factors and symptoms were calculated comparing Omicron cases to Delta cases identified over the same time period.
Results: By 14 December 2021, 1000 cases of the Omicron variant had been identified in Wales. Of the first 1000, just 3% of cases had a prior history of travel revealing rapid community transmission. A higher proportion of Omicron cases were identified in individuals aged 20-39, and most cases were double vaccinated (65.9%) or boosted (15.7%). Age-adjusted analysis also revealed that Omicron cases were less likely to be hospitalised (0.4%) or report symptoms (60.8%). Specifically a significant reduction was observed in the proportion of Omicron cases reporting anosmia (8.9%).
Conclusion: Key findings include a lower risk of anosmia and a reduced risk of hospitalisation in the first 1000 Omicron cases compared with co-circulating Delta cases. We also identify that existing measures for travel restrictions to control importations of new variants identified outside the United Kingdom did not prevent the rapid ingress of Omicron within Wales.

Keywords: COVID-19; Genomics; Omicron; SARS-CoV-2; Surveillance; Wales.
 
Back
Top Bottom